Lifitegrast is the active ingredient in the anti-inflammatory drug Xiidra®, used to treat dry eye syndrome. Recent literature data show that lifitegrast degrades into impurities under the influence of thermolysis, acidic and alkaline hydrolysis, and oxidation. To address the stability issue of lifitegrast and improve the existing drug formulation, the goal was to encapsulate lifitegrast within hyalurosomes and determine the impact of hyalurosomes on its stability. Hyalurosomes are nanometric vesicles, similar to liposomes, formed by the association of hyaluronic acid and phospholipid molecules. Generally, hyalurosomes are structures that can encapsulate active substances, thereby contributing to increased stability by physically isolating the drug from external conditions that may cause degradation. To optimize the preparation of liposomes and hyalurosomes, two methods were used, among which the hydration method, an environmentally friendly method that does not use organic solvents, produced the most uniform vesicles in terms of size, polydispersity index, and zeta potential. The physical characteristics (vesicle size, polydispersity index, and zeta potential) of hyalurosomes were compared with those of liposomes containing the same amount of phospholipids. Meanwhile, the stability of the vesicles was evaluated by monitoring the physical characteristics over a month at 5 °C and 25 °C. It was shown that the physical characteristics of hyalurosomes remained stable at both 5 °C and 25 °C, whereas for liposomes, size and polydispersity index remained stable, but the zeta potential showed a tendency to increase, which could potentially lead to liposome aggregation after a longer storage period. Forced degradation studies have shown that hyalurosome formulations with encapsulated lifitegrast are stable in terms of physical characteristics and lifitegrast content at 25 °C / 60% RH and 50 °C / 75% RH. However, when examining the effect of temperature on the oxidation of lifitegrast, changes were observed in the size and zeta potential of the hyalurosomes, sample pH, and lifitegrast content during storage. Formulations of hyalurosomes with the highest phospholipid concentration (60 mg/ml) retain a higher percentage of the initial lifitegrast content under both storage conditions (25 °C / 60 % RH + H2O2 i 50 °C / 75 % RH + H2O2) compared to the control samples. The obtained results pave the way for the potential use of hyalurosomes for the delivery of lifitegrast.